DNA sequencer Helicos BioSciences aims to raise $81M in IPO

Want to master the CMO role? Join us for GrowthBeat Summit on June 1-2 in Boston, where we'll discuss how to merge creativity with technology to drive growth. Space is limited and we're limiting attendance to CMOs and top marketing execs. Request your personal invitation here!

Helicos BioSciences, a Cambridge, Mass., developer of high-speed DNA and RNA sequencing technology, hopes to raise as much as $81 million in an initial offering, according to an SEC filing.

The company said in the filing that it hopes to offer 5.4 million shares at $13 to $15 per share. The IPO market for biotechs has been tepid recently, and several companies have recently either lowered their asking price or withdrawn their proposed offering altogether.

Helicos’ technology is designed to sequence single molecules of DNA or RNA at extremely high speeds, in hopes of making it economical to scan entire human, animal or pathogen genomes in real time.


VentureBeat’s VB Insight team is studying email marketing tools. Chime in here, and we’ll share the results.